News & Media

We share our journey of innovation and collaboration, bringing to light the impactful research and developments from our dedicated team. Keep an eye here for the latest coverage and breakthroughs that are setting new benchmarks in medical science.

Nanoligent grows its scientific team with the incorporation of two Torres Quevedo Scientists (03/06/2024)

The aim of the Torres Quevedo grant is to promote the professional growth of researchers and meet the demand in the private sector for highly skilled personnel capable of leading research and development projects. Additionally, it contributes to the consolidation of recently established technology companies.
Nanoligent grows its scientific team with the incorporation of two Torres Quevedo Scientists

Nanoligent Receives Innovation Recognition from Cerdanyola Empresarial (27/11/2023)

We are thrilled to announce that Nanoligent has been selected by the Associació d’Empreses de Cerdanyola del Vallès-Cerdanyola Empresarial to receive a coveted Innovation Recognition at the upcoming 10th Cerdanyola Business Night. The award ceremony, organized by Cerdanyola Empresarial, is set to take place on November 23rd at 8 pm at the Hotel Campus of the UAB.
Nanoligent Receives Innovation Recognition from Cerdanyola Empresarial

Nanoligent Joins Arquímedes Accelerator for Intensive Growth Program (21/11/2023)

Nanoligent is proud to announce its active participation in the Arquídemes Accelerator, a groundbreaking initiative in collaboration with Santander Bank (Universidades section). This first edition of the program is dedicated to fostering the growth of emerging companies, mainly spin-offs from the University.
Nanoligent Joins Arquímedes Accelerator for Intensive Growth Program

Nanoligent raised €2.8 M and completed Seed round financing with support of i&i Biotech Fund I (27/09/2022)

This press release highlights the following: «The seed round financing will allow Nanoligent to foster the development of multiple drug candidates and advance the pre-clinical development of its lead candidate in a variety of tumor types.»
Nanoligent raised €2.8 M and completed Seed round financing with support of i&i Biotech Fund I

Nanoligent raises €1M in Series Seed financing (03/02/2022)

This press release states the following: «The financing will allow Nanoligent to complete the pre-clinical development in a variety of tumor types and to move its lead candidate into pre-IND stage.»
Nanoligent raises €1M in Series Seed financing

Nanoligent raises 1 million euros for its cancer treatment using nanotechnology - El Periódico (03/02/2022)

This media highlights the following:
«The research team, led by Esther Vázquez and Antonio Villaverde, from the UAB, and Ramon Mangues, from the Sant Pau Hospital, have already created a prototype of the drug and conducted in vivo trials in animal models of colorectal cancer, which have demonstrated its efficacy, selective biodistribution, and low toxicity.»
Nanoligent raises 1 million euros for its cancer treatment using nanotechnology – El Periódico (spanish)

6th MEET2WIN European Oncology Partnering Convention (30/04/2021)

Nanoligent has been selected for pitching next May 5th in the Oncology Upward Investment session of the 6th edition of the MEET2WIN European Oncology Partnering Convention. MEET2WIN is an European Partnering Convention fully dedicated to open innovation in oncology.
6th MEET2WIN European Oncology Partnering Convention

28th Healthcare Investment Forum, 24th March 2021 (22/03/2021)

Nanoligent has been selected to showcase at the 28th Healthcare Investment Forum the next 24th of March. The Healthcare Barcelona Investment Forum is a meeting point for entrepreneurs and investors in the healthcare sector.
28th Healthcare Investment Forum, 24th March 2021

Bioengineering and Medtech against Cancer (11/11/2020)

Nanoligent has been selected to showcase at the pitch elevator session at the Bioengineering and Medtech against Cancer short course on the 25th of November. The course is organized by Medicen Paris and the Institute for Bioengineering of Catalonia (IBEC), with the collaboration of Biocat, “la Caixa” Foundation and Meditecnologia, under the framework of B·Debate
Bioengineering and Medtech against Cancer

BioFIT 2019 (13/12/2019)

Nanoligent was present in the 8th edition of the BioFIT partnering event that took place this past 10-11th of December in the French city of Marseille. We showcased our project in a 5-minute pitch during the Start-up Slam and established contact with potential partners and investors.
BioFIT 2019

PEGS Europe 2019 (23/11/2019)

This recent 18-22th of November Nanoligent was present in the 11th Annual PEGS Europe summit, the largest European event covering all aspects of protein and antibody engineering. This year the summit broke its previous attendance records, with more than 1,300 participants and 250 scientific posters.
PEGS Europe 2019

XVIII Farma-Biotech Cooperation Meeting (30/10/2019)

Last October 29th the employers’ organization of the pharmaceutical industry in Spain, Farmaindustria, organized its latest Farma-Biotech meeting to boost pre-clinical research.
XVIII Farma-Biotech Cooperation Meeting

Oncology Innovation with Nanoligent (01/08/2019)

This past August Nanoligent was featured in the Spanish economy newspaper elEconomista. After a brief review on the importance of technology improvements for cancer treatment, Nanoligent technology is highlighted for its selectivity, efficiency, and low toxicity.
Oncology Innovation with Nanoligent

Nanoligent awarded 1st prize in ONCO Emergence Forum Barcelona 2018 (13/12/2018)

The ONCO Emergence forum took place last June 21-22th at the Fira Gran Via (Barcelona). It is a networking conference focused on setting up transnational collaboration projects in the field of oncology and promotes interaction among research institutes, companies and medical facilities.

Nanoligent awarded 1st prize in ONCO Emergence Forum Barcelona 2018

Nanoligent featured in national press (10/09/2018)

This past September Nanoligent technology was featured in the health section of the Spanish national newspaper ABC. The capacity to selectivity kill metastatic stem cells, and thus, reduce the overall toxicity of the treatment is highlighted as the main strength of Nanoligent’s technology.
Nanoligent featured in national press

Spain develops the first drug to prevent metastasis in colorectal cancer - El Confidencial (07/09/2018)

El Confidencial, whose Science section is one of the most prestigious and relevant of all Spanish newspapers, highlights the following: «The research team, led by Esther Vázquez and Antonio Villaverde, from the UAB, and Ramon Mangues, from the Sant Pau Hospital, have already created a prototype of the drug and conducted in vivo trials in animal models of colorectal cancer, which have demonstrated its efficacy, selective biodistribution, and low toxicity.»
Spain develops the first drug to prevent metastasis in colorectal cancer – El Confidencial (spanish)

Nanoligent develops a new anticancer drug - La Vanguardia (06/06/2018)

This newspaper highlights the following:
«Researchers from the Institute of Biotechnology and Biomedicine at the Autonomous University of Barcelona (UAB), from the Research Institute of the Hospital de la Santa Creu i Sant Pau, and from the CIBER of Bioengineering, Biomaterials, and Nanomedicine have launched a ‘spin-off’ that aims to create a drug that eliminates cancer stem cells.»
Nanoligent develops a new anticancer drug – La Vanguardia (spanish)

The UAB creates a company to develop a nanomedicine against cancer - Cadena COPE (06/06/2018)

The COPE radio station, one of the most prestigious in Spain, states the following: «The research team, led by Esther Vázquez and Antonio Villaverde, from the UAB, and Ramon Mangues, from the Sant Pau Hospital, have already created a prototype of the drug and conducted in vivo trials in animal models of colorectal cancer, which have demonstrated its efficacy, selective biodistribution, and low toxicity.»
The UAB creates a company to develop a nanomedicine against cancer – Cadena COPE (spanish)

Nova spin-off de la UAB per desenvolupar una nanomedicina per al tractament del càncer - UAB Press Room (06/06/2018)

This media highlights the following:
«The research team, led by Esther Vázquez and Antonio Villaverde, from the UAB, and Ramon Mangues, from the Sant Pau Hospital, have already created a prototype of the drug and conducted in vivo trials in animal models of colorectal cancer, which have demonstrated its efficacy, selective biodistribution, and low toxicity.»
Nanoligent desarrolla nuevo fármaco anticanceroso – UAB (catalan)